Navigation Links
Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
Date:10/20/2009

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream. During invitro studies, the Hemopurifier® removed 68% of H1N1 virus from blood plasma in 30 minutes, 80% of the virus in two hours, and a 96% reduction of H1N1 was observed at six hours. The studies were performed by third party researchers approved by the United States Department of Health and Human Services (HHS) to house and conduct research on the current pandemic strains of H1N1 virus.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

"The confirmation of the same Hemopurifier® we are advancing in Hepatitis-C (HCV) care, having significant activity against H1N1 virus is quite timely when considering the evolving rate of the pandemic," stated Aethlon Chairman & CEO, Jim Joyce. At present, the 2009 H1N1 influenza virus is the predominant influenza virus in circulation in most countries worldwide. Additional information on the virus, including situational updates can be accessed online at http://www.cdc.gov/H1N1flu.

Previous studies of the Hemopurifier® also demonstrated the ability of the device to capture both the reconstructed Spanish flu of 1918 virus (1918rv) and the H5N1 avian influenza virus (Bird Flu). As an adjunct therapy, the Hemopurifier® offers to improve the benefit of antiviral drugs against highly virulent strains of influenza and provides a therapeutic option against emerging strains of influenza that are resistant to drug and vaccine therapies.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions, including H1N1 influenza, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

    Contacts:

    RedChip Companies, Inc.
    Jon Cunningham
    1-800-733-2447, Ext. 107
    Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com

SOURCE Aethlon Medical, Inc.


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
2. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
3. Premier Research Names Bernard Sweeney as Executive Director, Medical Devices
4. Starch Medical Launches Novel Plant Sourced Surgical Hemostatic Pad
5. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
6. ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity
7. Circle Medical Devices, Texcel Medical Merge to Form CIRTEC Medical Systems
8. Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent
9. Larry King to Host 10th Annual American Friends of Rabin Medical Center Broadway on the Hudson Gala
10. ATS Medical Products Featured Prominently at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting
11. AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):